Fireman B.V. (IFRX)

$IFRX when lambo?

$IFRX worst case would be a clueless offering just to get some money…

$IFRX The recent 6-K filing confirms that InflaRx is officially shifting into high gear. By approving the LTIP 2026 and—more importantly—implementing the strategic amendment to the Articles of Association (Article 34), the company has cleared the final legal hurdles for a major move. Friday’s massive volume and price surge wasn’t a coincidence; it was the market front-running this newfound structural flexibility. The automatic increase in authorized capital is a classic 'setup' for a large-scale entry by a strategic partner or a significant investment from Big Pharma. Management has secured the tools they need to execute. While the market waits for the official ink on a deal, the infrastructure for a massive valuation re-rating is now fully in place. The groundwork is done—now we wait for the trigger.

$IFRX https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319974475&type=PDF&symbol=IFRX&cdn=9da4b03616b906578627a25d4f6de4e8&companyName=InflaRx+N.V.&formType=6-K&formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&dateFiled=2026-04-23 Fawk!

$IFRX I think next week we should see the cmd announcement

$IFRX consolidation for launch above $ 2 - All the best!

$IFRX Der Kurs bewegt sich gar nicht. Schon erstaunlich in Deutschland bewegt der Kurs schon bei 3000 Aktien um 8Prozent.

$IFRX deals are done on weekends 🤑💪

$IFRX Offering coming.

$IFRX Don't go a year without an offering. This year should be the third or fourth in a row, not counting the money received from the German government, which hasn't produced any useful results, just announcements and failures. The only solution is a sell-off, but they have to make an offering first; even a partner wants to see the money.

$IFRX 250K volume in 20 min from the opening. Will be a great day! Weak hands please finish exiting so we can get on with our growth!!

$IFRX At the Oppenheimer event a couple months back, there were two questions: more info on the AAV opportunity, and HS pain reduction. No ongoing in-house study, no revenue, just a mysterious pending CMD to talk science and detail the HS study plan moving forward, the best scenario of which likely giving topline Q4 2027. None of these analysts can build partnership value into their shot-in-the-dark spreadsheets. At best, any relative number change is a measure of company PR substance – event attendance doesn’t count – no substance of value PR in the last two months that’s for sure. So what Andreas is saying: nothing of value announced recently? That’ll cost you a 30% hit in my pt. Who cares. This is an elusive partnership-hope investment at this stage, valuation can (and will) change overnight. Get on with it. Any of these analyst dudes want to talk about what really matters, the biology, as to value, let’s go. You CAN build that into your value models.

$IFRX Oppenheimer analyst Andreas Argyrides assumed coverage of InflaRx N.V. (IFRX) with an Outperform rating in April 2026, highlighting the clinical-stage biopharmaceutical company's focus on its C5a/C5aR pathway technology. The company is developing izicopan (oral) and vilobelimab (intravenous) for inflammatory diseases, with previous analyst notes raising price targets as high as $7. Yahoo Finance Yahoo Finance +3 Key details: Company Focus: InflaRx is a German-based firm focused on advancing izicopan (INF904), an oral C5aR1 inhibitor for inflammatory and immunology (I&I) indications, and vilobelimab for acute respiratory distress syndrome (ARDS). Strategy: The company has streamlined its strategy to focus on terminal complement inhibition to manage tissue damage in inflammatory conditions. Analyst View: Oppenheimer maintains an Outperform rating, indicating a positive outlook on the company's prospects, often following developments related to their drug candidates and trial data. Rece

$IFRX https://anachart.com/wp-content/uploads/ana_temp/1777035689_soc-img.jpg

$IFRX Oppenheimer resumes coverage of IFRX with an Outperform and lowers their tgt to $5 from $7. Analyst Mazahir Alimohamed offered, "We are assuming coverage of InflaRx (IFRX) with an Outperform rating and $5 PT. We view izicopan (INF904), an oral C5aR inhibitor with a differentiated pharmacological profile vs. avacopan (TAVNEOS; approved for ANCA-associated vasculitis [AAV]), as IFRX's main value driver. Backed by promising Ph2a basket study data (link), InflaRx is advancing izicopan to Ph2b in hidradenitis suppurativa (HS), which to us is the primary near-term development focus. Simultaneously, we see AAV as a compelling and increasingly relevant upside opportunity. InflaRx continues to engage with potential collaborators to unlock broader pipeline-in-a-product potential across I&I indications. Against a backdrop of strong interest in the complement space (Biogen's Apellis acquisition, Vanqua Bio licensing), we view izicopan as a compelling potential partnership candidate."

$IFRX When do you see a partnership announcement? 3-6 more months?

$IFRX secured shareholder approval for its annual accounts, auditor, board discharge, and share-issuance authorities.

$IFRX so reassuring to see healthcare in this country is being run by the sharpest minds https://twitter.com/atrupar/status/2047397140255633528?s=61

$IFRX Results of Annual General Meeting of Shareholders On April 23, 2026, InflaRx N.V. (the “Company”) held its Annual General Meeting of Shareholders (the “Annual General Meeting”). The final results of each of the agenda items submitted to a vote of the shareholders are as follows: Agenda Item 3. Adoption of Dutch statutory annual accounts for the financial year ended December 31, 2025. The Company shareholders approved the adoption of Dutch statutory annual accounts for the financial year ended December 31, 2025. Agenda Item 5. Instruction to KPMG Accountants N.V. for the external audit of the Company’s statutory annual accounts for the financial year 2026. The Company shareholders approved the instruction to KPMG Accountants N.V. for the external audit of the Company’s statutory annual accounts for the financial year 2026. Agenda Item 6. Release from liability for the Company’s directors with respect to the performance of their duties during the financial year ended December 31, 2025. The Company shareholders approved the release from liability for the Company’s directors with respect to the performance of their duties during the financial year ended December 31, 2025. Agenda Item 7. Re-appointment of Mr. Niels Riedemann as executive director of the Company. The Company shareholders approved the re-appointment of Mr. Niels Riedemann as executive director of the Company. Agenda Item 8. Re-appointment of Mr. Renfeng Guo as executive director of the Company. The Company shareholders approved the re-appointment of Mr. Renfeng Guo as executive director of the Company. Agenda Item 9. Re-appointment of Mr. Nicolas Fulpius as non-executive director of the Company. The Company shareholders approved the re-appointment of Mr. Nicolas Fulpius as non-executive director of the Company. Agenda Item 10. Re-appointment of Mr. Richard Brudnick as non-executive director of the Company. The Company shareholders approved the re-appointment of Mr. Richard Brudnick as non-executive director of the Company. Agenda Item 11. Re-appointment of Ms. Hege Hellstrom as non-executive director of the Company. The Company shareholders approved the re-appointment of Ms. Hege Hellstrom as non-executive director of the Company. Agenda Item 12. Extension of authorization for the Company’s board of directors (the “Board”) to issue shares and grant rights to subscribe for shares. The Company shareholders approved the extension of authorization for the Company’s Board to issue shares and grant rights to subscribe for shares. Agenda Item 13. Extension of authorization for the Board to limit and exclude pre-emption rights. The Company shareholders approved the extension of authorization for the Board to limit and exclude pre-emption rights. Agenda Item 14. Extension of authorization for the Board to acquire shares and depository receipts for shares in the Company’s capital. The Company shareholders approved the extension of authorization for the Board to acquire shares and depository receipts for shares in the Company’s capital. Agenda Item 15. Amendment to the Company’s articles of association. The Company shareholders approved the amendment to the Company’s articles of association. Agenda Item 16. Approval of a new Long-Term Incentive Plan (the “LTIP 2026”). The Company shareholders approved the LTIP 2026. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INFLARX N.V. Date: April 23, 2026 By: /s/ Niels Riedemann Name: Niels Riedemann Title: Chief Executive Officer

$IFRX tomorrow will be a Green Day. I just wonder if we will be able to reach the 80s.

$IFRX damn it almost had it there at the last minute

$IFRX what do you think, will there some boosting news tomorrow morning?